Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study.

Martin A, Nachury M, Peyrin-Biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N, Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A.

J Crohns Colitis. 2020 Jan 13. pii: jjaa005. doi: 10.1093/ecco-jcc/jjaa005. [Epub ahead of print]

PMID:
31930285
2.

Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM).

Capron M, Béghin L, Leclercq C, Labreuche J, Dendooven A, Standaert A, Delbeke M, Porcherie A, Nachury M, Boruchowicz A, Dupas JL, Fumery M, Paupard T, Catteau S, Deplanque D, Colombel JF, Desreumaux P.

J Clin Med. 2019 Dec 24;9(1). pii: E41. doi: 10.3390/jcm9010041.

3.

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.

Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*.

Aliment Pharmacol Ther. 2020 Mar;51(5):553-564. doi: 10.1111/apt.15609. Epub 2019 Dec 22.

PMID:
31867766
4.

Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn's Disease.

Hallé E, Azahaf M, Duveau N, Lambin T, Nachury M, Branche J, Gérard R, Lauriot Dit Prevost C, Wils P, Desreumaux P, Ernst O, Pariente B.

Dig Dis Sci. 2019 Dec 6. doi: 10.1007/s10620-019-05979-8. [Epub ahead of print]

PMID:
31811438
5.

Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.

Painchart C, Brabant S, Duveau N, Nachury M, Desreumaux P, Branche J, Gérard R, Prevost CLD, Wils P, Lambin T, Boualit M, Labalette M, Pariente B.

Dig Dis Sci. 2019 Oct 10. doi: 10.1007/s10620-019-05865-3. [Epub ahead of print]

PMID:
31599389
6.

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.

Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Richard D, Pereira B, Goutte M, Buisson A; POPCUR study group.

Clin Gastroenterol Hepatol. 2019 Aug 27. pii: S1542-3565(19)30916-4. doi: 10.1016/j.cgh.2019.08.041. [Epub ahead of print]

PMID:
31470175
7.

Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis.

Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-Biroulet L; PROTECT-GETAID study group.

Clin Gastroenterol Hepatol. 2020 Mar;18(3):620-627.e1. doi: 10.1016/j.cgh.2019.05.060. Epub 2019 Jun 13.

8.

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.

Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID.

Aliment Pharmacol Ther. 2019 Jul;50(1):40-53. doi: 10.1111/apt.15294. Epub 2019 Jun 5.

PMID:
31165509
9.

Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease.

Sokol H, Brot L, Stefanescu C, Auzolle C, Barnich N, Buisson A, Fumery M, Pariente B, Le Bourhis L, Treton X, Nancey S, Allez M, Seksik P; REMIND Study Group Investigators.

Gut. 2020 Mar;69(3):462-472. doi: 10.1136/gutjnl-2019-318719. Epub 2019 May 29.

PMID:
31142586
10.

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease.

Bouguen G, Huguet A, Amiot A, Viennot S, Cholet F, Nachury M, Flamant M, Reimund JM, Desfourneaux V, Boureille A, Siproudhis L; GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives).

Clin Gastroenterol Hepatol. 2020 Mar;18(3):628-636. doi: 10.1016/j.cgh.2019.05.027. Epub 2019 May 22.

11.

Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease.

Hammoudi N, Cazals-Hatem D, Auzolle C, Gardair C, Ngollo M, Bottois H, Nancey S, Pariente B, Buisson A, Treton X, Fumery M, Bezault M, Seksik P, Le Bourhis L; REMIND Study Group Investigators, Flejou JF, Allez M.

Clin Gastroenterol Hepatol. 2020 Jan;18(1):141-149.e2. doi: 10.1016/j.cgh.2019.04.045. Epub 2019 Apr 28.

PMID:
31042575
12.

T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence.

Allez M, Auzolle C, Ngollo M, Bottois H, Chardiny V, Corraliza AM, Salas A, Perez K, Stefanescu C, Nancey S, Buisson A, Pariente B, Fumery M, Sokol H, Tréton X, Barnich N, Seksik P, Le Bourhis L; REMIND Study Group.

Gut. 2019 Nov;68(11):1961-1970. doi: 10.1136/gutjnl-2018-317878. Epub 2019 Feb 12.

PMID:
30792246
13.

Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease.

Paccou J, Nachury M, Duchemin C, Desreumaux P, Flipo RM, Pariente B.

Joint Bone Spine. 2019 Oct;86(5):654-656. doi: 10.1016/j.jbspin.2019.01.008. Epub 2019 Jan 31. No abstract available.

PMID:
30711690
14.

NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.

Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°.

Gut. 2019 Aug;68(8):1396-1405. doi: 10.1136/gutjnl-2018-317371. Epub 2018 Nov 17.

PMID:
30448772
15.

Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.

Pellet G, Stefanescu C, Carbonnel F, Peyrin-Biroulet L, Roblin X, Allimant C, Nachury M, Nancey S, Filippi J, Altwegg R, Brixi H, Fotsing G, de Rosamel L, Shili S, Laharie D; Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):494-501. doi: 10.1016/j.cgh.2018.08.081. Epub 2018 Sep 10.

PMID:
30213584
16.

Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study.

Auzolle C, Nancey S, Tran-Minh ML, Buisson A, Pariente B, Stefanescu C, Fumery M, Marteau P, Treton X, Hammoudi N; REMIND Study Group Investigators, Jouven X, Seksik P, Allez M.

Aliment Pharmacol Ther. 2018 Nov;48(9):924-932. doi: 10.1111/apt.14944. Epub 2018 Aug 20.

PMID:
30126030
17.

Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID).

Gagnière C, Bourrier A, Seksik P, Gornet JM, DeWit O, Nancey S, Altwegg R, Abitbol V, Laharie D, Reenaers C, Buisson A, Pariente B, Viennot S, Vuitton L, Stefanescu C, Marteau P, Bouguen G, Cosnes J, Amiot A; GETAID INFOPRO study group.

Aliment Pharmacol Ther. 2018 Oct;48(7):713-722. doi: 10.1111/apt.14926. Epub 2018 Aug 2.

PMID:
30069921
18.

Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis.

de Chambrun GP, Nachury M, Funakoshi N, Gerard R, Bismuth M, Valats JC, Panaro F, Navarro F, Desreumaux P, Pariente B, Blanc P.

Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1247-1252. doi: 10.1097/MEG.0000000000001223.

PMID:
30052539
19.

Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.

Altwegg R, Combes R, Laharie D, De Ledinghen V, Radenne S, Conti F, Chazouilleres O, Duvoux C, Dumortier J, Leroy V, Treton X, Durand F, Dharancy S, Nachury M, Goutorbe F, Lamblin G, Boivineau L, Peyrin-Biroulet L, Pageaux GP.

Dig Liver Dis. 2018 Jul;50(7):668-674. doi: 10.1016/j.dld.2018.02.014. Epub 2018 Mar 13.

PMID:
29655972
20.

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.

Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators.

Gastroenterology. 2018 Apr;154(5):1334-1342.e4. doi: 10.1053/j.gastro.2017.12.020. Epub 2017 Dec 24.

PMID:
29277560

Supplemental Content

Loading ...
Support Center